Caring Ambassadors Hepatitis C Program Newsletter

July 2010


Clinical Trials, Cohort Studies, Pilot Studies


Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis C. Matsui K, Iwabuchi S, Shimizu H, et al. Hepatol Res. 2010 Jun 8. [Epub ahead of print]


Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Diago M, Shiffman ML, Bronowicki JP, et al. Hepatology. 2010 Jun;51(6):1897-903.


Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load. Arase Y, Suzuki F, Akuta N, et al. Intern Med. 2010;49(11):957-63. Epub 2010 Jun 1.


Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: Results from a cohort study.

Bruneau J, Daniel M, Kestens Y, Abrahamowicz M, Zang G. Int J Drug Policy. 2010 Jun 10. [Epub ahead of print]


Metabolic disorders associated with chronic hepatitis C: impact of genotype and ethnicity.

Sersté T, Nkuize M, Moucari R, et al. Liver Int. 2010 Jun 9. [Epub ahead of print]


Influence of body mass index on outcome of pediatric chronic hepatitis c virus infection. Delgado-Borrego A, Healey D, Negre B, et al. J Pediatr Gastroenterol Nutr. 2010 Jun 3. [Epub ahead of print]


Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas. Chuang SS, Liao YL, Chang ST, et al. J Clin Pathol. 2010 Jun 7. [Epub ahead of print]


Nail changes in patients with liver disease. Salem A, Gamil H, Hamed M, Galal S. J Eur Acad Dermatol Venereol. 2010 Jun;24(6):649-54. Epub 2009 Nov 2.


The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C. Carneiro MV, Souza FF, Teixeira AC, et al. Eur J Gastroenterol Hepatol. 2010 Jun 15. [Epub ahead of print]


Basic and Applied Science, Pre-Clinical Studies


Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Thompson AJ, Fellay J, Patel K, et al. Gastroenterology. 2010 Jun 11. [Epub ahead of print]


Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. Kurbanov F, Tanaka Y, Matsuura K, et al. J Infect Dis. 2010 Jun 1;201(11):1663-71.


Wild-type hepatitis C virus core inhibits the initiation of antigen-specific T- and B-cell immune responses in BALB/c mice. Zhu W, Chang Y, Wu C, Han Q, Pei R, Lu M, Chen X. Clin Vaccine Immunol. 2010 Jun 2. [Epub ahead of print]


PSI-7851, a Pronucleotide of {beta}-D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate: A potent and pan-genotype inhibitor of hepatitis c virus replication.

Lam AM, Murakami E, Espiritu C, et al. Antimicrob Agents Chemother. 2010 Jun 1. [Epub ahead of print]


Phosphoramidate ProTides of 2'-C-Methylguanosine as highly potent inhibitors of hepatitis c virus. Study of their in vitro and in vivo properties. McGuigan C, Gilles A, Madela K, et al. J Med Chem. 2010 Jun 8. [Epub ahead of print]


Prediction of prognostic biomarkers for Interferon-based therapy to Hepatitis C Virus patients : a metaanalysis of the NS5A protein in subtypes 1a, 1b, and 3a. Elhefnawi MM, Zada S, El-Azab IA. Virol J. 2010 Jun 15;7(1):130. [Epub ahead of print]


Association of NKG2A with treatment for chronic hepatitis C virus infection. Harrison RJ, Ettorre A, Little AM, Khakoo SI. Clin Exp Immunol. 2010 Jun 9. [Epub ahead of print]


Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Chandra PK, Hazari S, Poat B, et al.

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Li JH, Lao XQ, Tillmann HL, et al. Hepatology. 2010 Jun;51(6):1904-11.


Hepatocyte growth factor and chronic hepatitis C. Marín-Serrano E, Rodríguez-Ramos C, Díaz-García F, et al. Rev Esp Enferm Dig. 2010 Jun;102(6):365-71.


HIV/HCV Coinfection


The impact of HIV/HCV co-infection on health care utilization and disability: Results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort.

Linas BP, Wang B, Smurzynski M, et al. J Viral Hepat. 2010 Jun 9. [Epub ahead of print]


Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. Ryan P, Resino S, Miralles P, Cosín J, et al. J Acquir Immune Defic Syndr. 2010 Jun 23. [Epub ahead of print]


Clearance of hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from peripheral blood mononuclear cells. Page EE, Cox A, Atkins M, Nelson MR. AIDS. 2010 Jun 1;24(9):1267-71.


Impact of hepatitis C virus coinfection on HAART in HIV-infected individuals: multi-centric observation cohort. Fuping G, Wei L, Yang H, et al. J Acquir Immune Defic Syndr. 2010 Jun;54(2):137-42.


Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. Asmuth DM, Murphy RL, Rosenkranz SL, et al. J Infect Dis. 2010 Jun 1;201(11):1686-96.


The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. Howard AA, Hoover DR, Anastos K, et al. J Acquir Immune Defic Syndr. 2010 Jun;54(2):152-9.


Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV. Proeschold-Bell RJ, Blouin R, Reif S, et al. South Med J. 2010 Jun 4. [Epub ahead of print]


Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009. Zhou S, Zhao Y, He Y, et al. J Acquir Immune Defic Syndr. 2010 Jun;54(2):191-6.


Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. Frank AC, Zhang X, Katsounas A, et al. J Interferon Cytokine Res. 2010 Jun;30(6):427-31. Bharucha JP,


Need to improve routine HIV testing of U.S. Veterans in care: Results of an internet survey.

Valdiserri RO, Nazi K, McInnes DK, Ross D, Kinsinger L. J Community Health. 2010 Jun;35(3):215-9.


Complementary and Alternative Medicine


Acupuncture for depression and myalgia in patients with hepatitis: an observational study.

Tufan ZK, Arslan H, Yildiz F, et al. Acupunct Med. 2010 Jun 7. [Epub ahead of print]


Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C.

Gomez EV, Perez YM, Sanchez HV, et al. World J Gastroenterol. 2010 Jun 7;16(21):2638-47.


Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease. Muntoni S, Rojkind M, Muntoni S. World J Gastroenterol. 2010 Jun 21;16(23):2889-94.


Epidemiology, Diagnostics, and Miscellaneous Works


A novel duplex real-time reverse transcriptase-polymerase chain reaction assay for the detection of hepatitis C viral RNA with armored RNA as internal control. Meng S, Li J. Virol J. 2010 Jun 7;7(1):117. [Epub ahead of print]


Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. Moura AS, Carmo RA, Teixeira AL, Leite VH, Rocha MO. Eur J Clin Microbiol Infect Dis. 2010 Jun 18. [Epub ahead of print]


Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Cheong JY, Um SH, Seo YS, et al. Dig Dis Sci. 2010 Jun 29. [Epub ahead of print]


Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success. Cooper C. Can J Gastroenterol. 2010 Jun;24(6):385-90.


Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco Counties, 2007. Cooper EN, Dodson C, Stopka TJ, et al.  J Urban Health. 2010 Jun 12. [Epub ahead of print]


Current risks of occupational blood-borne viral infection. Mohebati A, Davis JM, Fry DE. Surg Infect (Larchmt). 2010 Jun;11(3):325-31.


Chronic hepatitis C in the state prison system: insights into the problems and possible solutions. Imperial JC. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):355-64.


Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Liver Transpl. 2010 Jun;16(6):748-59.


Development of a low-cost real-time reverse transcriptase-polymerase chain reaction technique for the detection and quantification of hepatitis C viral load. Shahzamani K, Merat S, Rezvan H, et al. Clin Chem Lab Med. 2010 Jun;48(6):777-84.


How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. Ciesek S, Friesland M, Steinmann J, et al. J Infect Dis. 2010 Jun 15;201(12):1859-66.


The role of physician and nurse attitudes in the health care of injecting drug users.

Brener L, Von Hippel W, Kippax S, Preacher KJ. Subst Use Misuse. 2010 Jun;45(7-8):1007-18.


Patient preferences and assessment of likely adherence to hepatitis C virus treatment.

Brett Hauber A, Mohamed AF, Beam C, Medjedovic J, Mauskopf J. J Viral Hepat. 2010 Jun 22. [Epub ahead of print]


Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Fischer GE, Schaefer MK, Labus BJ, et al. Clin Infect Dis. 2010 Jun 24. [Epub ahead of print]


Epidemiology, Surveillance, and Prevention of Hepatitis C Virus Infections in Hemo-dialysis Patients. Patel PR, Thompson ND, Kallen AJ, Arduino MJ. Am J Kidney Dis. 2010 Jun 4. [Epub ahead of print]


The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009.

Roberts SS, Miller RK, Jones JK, et al. Birth Defects Res A Clin Mol Teratol. 2010 Jun 17. [Epub ahead of print]